Why SahmAdrangi is a Role Model

A former Wall Street bond trader reached out to me after writing an epic piece: An Ode To Those Who Wander. The individual was also a hedge fund credit analyst and hedge fund portfolio manager. He wanted to discuss GNC Holdings, Inc. We carried out the conversation over the weekend. SahmAdrangi cited that he had been keenly following my work on the company and had been building a large position in his PA.

About the Piece

The article will outline the former bond trader’s experiences at Wall Street. After graduating from Penn State, SahmAdrangi worked as an intern at the credit desk of Merrill Lynch in NYC. He continued to work at the company for the next three years because of his hard work. He worked at a bond desk where he traded credit. He also incorporated his skills into a credit trading duty at Longacre, a $3 billion hedge fund. While there, the former bond trader interacted with Sahm, the current hedge fund founder of the prestigious Kerrisdale Capital.

The former bond trader also worked on Paulson &Co’s credit team and made a whopping $6 billion shorting mortgage bonds. He was also a credit PM at the renowned Bowery Investment Management for three years. The former bond trader decided to exit the Wall Street in June 2015. He cited that he spent many hours working at the company and the high cost of living in the city stimulated his resignation. Even so, he still enjoys investing, and he is currently generating income from decent securities selections.

An Overview of Sahm

Sahm is the talented Chief Investment Officer and sole founder of Kerrisdale Capital Management. Sahm is a credited author and publisher who shares Kerrisdale Capital’s insights on stock including overhyped shorts and under-followed longs, which are misinterpreted by the market. Sahm became popular after exposing fake Chinese companies such as China Biotics and China Marine Food Group. He has also focused the efforts of his firm on sectors that have enabled Kerrisdale Capital to develop expertise. For instance, the firm has focused on the biotechnology sector where it has published research concerning development stage companies like Unilife.